Lead Product(s) : CLS001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Hangzhou Celregen Therapeutics
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Details : Under the Agreement, Celregen will have the exclusive right to develop, manufacture and commercialize CLS001 for bullous keratopathy in the Greater China region, including Mainland China, Hong Kong, Macau and Taiwan.
Product Name : CLS001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 09, 2022
Lead Product(s) : CLS001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Hangzhou Celregen Therapeutics
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Arctic Vision
Deal Size : $35.0 million
Deal Type : Licensing Agreement
Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...
Product Name : AE101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 14, 2021
Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Arctic Vision
Deal Size : $35.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Vandefitemcel
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : OcuMension Therapeutics
Deal Size : $71.0 million
Deal Type : Agreement
Details : Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.
Product Name : SB623
Product Type : Cell and Gene therapy
Upfront Cash : $6.0 million
March 31, 2020
Lead Product(s) : Vandefitemcel
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : OcuMension Therapeutics
Deal Size : $71.0 million
Deal Type : Agreement